For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Most weight loss drugs were meant to be administered as treatment for those with Type 2 Diabetes Mellitus (T2DM), and weight ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

New research suggests popular weight loss medications containing semaglutide may increase risk of rare vision condition, but ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...